Strategies to improve drug development for sepsis

Nature Reviews Drug Discovery

Volumn 13, Issue 10, 2014, Pages 741-758

  Fink, Mitchell P ^a   Shaw Warren, H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 3 BROMO 5 [N PHENYL N [2 [[2 (1,2,3,4 TETRAHYDRO 2 ISOQUINOLYLCARBONYLOXY)ETHYL]CARBAMOYL]ETHYL]CARBAMOYL] 1 PROPYLPYRIDINIUM NITRATE; ANTIINFECTIVE AGENT; APAFANT; BAYX 1351; CENTOXIN; DELTIBANT; DEXAMETHASONE; DROTRECOGIN; ERITORAN; ETANERCEPT; FILGRASTIM; FLUDROCORTISONE; GINKGOLIDE B; GR 270773; HYDROCORTISONE; IBUPROFEN; IMMUNOGLOBULIN G; LEXIPAFANT; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E5; RECOMBINANT HUMAN BACTERICIDAL PERMEABILITY INCREASING PROTEIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT THROMBOMODULIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RESATORVID; SARGRAMOSTIM; TALACTOFERRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CLINICAL PRACTICE; CONTINUOUS INFUSION; DISEASE MARKER; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; GRAM NEGATIVE INFECTION; GRAM NEGATIVE SEPSIS; HUMAN; LOW DRUG DOSE; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESPIRATORY FAILURE; REVIEW; SEPSIS; SEPTIC SHOCK; T LYMPHOCYTE; ANIMAL; DRUG DESIGN; METHODOLOGY; MICROBIOLOGY; MOLECULARLY TARGETED THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SEPSIS;

EID: 84921815675     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4368     Document Type: Review

References (178)

1. Schulte, W., Bernhagen, J. & Bucala, R. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets-an updated view. Mediators Inflamm. 2013, 165974 (2013).
2. Aziz, M., Jacob, A., Yang, W. L, Matsuda, A. & Wang, P. Current trends in inflammatory and immunomodulatory mediators in sepsis. J. Leukoc. Biol. 93, 329-342 (2013).
3. Nduka, O. O. & Parrillo, J. E. The pathophysiology of septic shock. Crit. Care Clin. 25, 677-702 (2009).
4. Galley, H. F. Oxidative stress and mitochondrial dysfunction in sepsis. Br. J. Anaesthesia 107, 57-64 (2011).
5. Levy, M. M. et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31, 1250-1256 (2003).
6. Angus, D. C. et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303-1310 (2001).
7. Martin, G. S., Mannino, D. M., Eaton, S. & Moss, M. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348, 1546-1554 (2003).
8. Gaieski, D. F., Edwards, J. M., Kallan, M. J. & Carr, B. G. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit. Care Med. 41, 1167-1174 (2013).
9. Vincent, J. L. et al. Sepsis in European intensive care units: results of the SOAP study. Crit. Care Med. 34, 344-353 (2006).
10. Stevenson, E. K., Rubenstein, A. R., Radin, G. T., Wiener, R. S. & Walkey, A. J. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit. Care Med. 42, 625-631 (2013).
11. Kaukonen, K. M., Bailey, M., Suzuki, S., Pilcher, D. & Bellomo, R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 311, 1308-1316 (2014).
12. Roch, A. et al. Outcome of acute respiratory distress syndrome patients treated with extracorporeal membrane oxygenation and brought to a referral center. Intensive Care Med. 40, 74-83 (2014).
13. Cheng, A. et al. Survival of septic adults compared with nonseptic adults receiving extracorporeal membrane oxygenation for cardiopulmonary failure: a propensity-matched analysis. J. Crit. Care 28, 532.e1-532.e10 (2013).
14. Bone, R. C. et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101, 1644-1655 (1992).
15. Vincent, J. L, Opal, S. M., Marshall, J. C. & Tracey, K. J. Sepsis definitions: time for change. Lancet 381, 774-775 (2013).
16. Wacker, C, Prkno, A., Brunkhorst, F M. & Schlattmann, P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect. Dis. 13, 426-435 (2013).
17. Huttunen, R. et al. High plasma level of long pentraxin 3 (PTX3) is associated with fatal disease in bacteremic patients: a prospective cohort study. PLoS ONE 6, e17653 (2011).
18. Uusitalo-Seppälä, R. et al. Pentraxin 3 (PTX3) is associated with severe sepsis and fatal disease in emergency room patients with suspected infection: a prospective cohort study. PLoS ONE 8, e53661 (2013).
19. Kim, S., Mi, L. & Zhang, L. Specific elevation of DcR3 in sera of sepsis patients and its potential role as a clinically important biomarker of sepsis. Diagnost. Microbiol. Infect. Dis. 73, 312-317 (2012).
20. Cid, J., Aguinaco, R., Sánchez, R., García-Pardo, G. & Llorente, A. Neutrophil CD64 expression as marker of bacterial infection: a systematic review and metaanalysis. J. Infection 60, 313-319 (2010).
21. Wong, H. R., Lindsell, C. J., Lahni, P., Hart, K. W & Gibot, S. Interleukin 27 as a sepsis diagnostic biomarker in critically ill adults. Shock 40, 382-386 (2013).
22. Wu, Y. et al. Accuracy of plasma sTREM-1 for sepsis diagnosis in systemic inflammatory patients: a systematic review and meta-analysis. Crit. Care 16, R229 (2012).
23. Angus, D. C. & van der Poll, T Severe sepsis and septic shock. N. Engl. J. Med. 369, 840-851 (2013).
24. Diener, K. R., Al-Dasooqi, N., Lousberg, E. L. & Hayball, J. D. The multifunctional alarmin HMGB1 with roles in the pathophysiology of sepsis and cancer. Immunol. Cell Biol. 91, 443-450 (2013).
25. Fink, M. P. Bench-to-bedside review: cytopathic hypoxia. Crit. Care 6, 491-499 (2002).
26. Brealey, D. et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 360, 219-223 (2002).
27. Singer, M. Mitochondrial function in sepsis: acute phase versus multiple organ failure. Crit. Care Med. 35, S441-S448 (2007).
28. Hotchkiss, R. S., Monneret, G. & Payen, D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect. Dis. 13, 260-268 (2013).
29. Yates, S. P., Jørgensen, R., Andersen, G. R. & Merrill, A. R. Stealth and mimicry by deadly bacterial toxins. Trends Biochem. Sci. 31, 123-133 (2006).
30. Ziegler, E. J. et al. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 307, 1225-1230 (1982).
31. Scheinman, R. I., Cogswell, P. C, Lofquist, A. K. & Baldwin, A. S. Jr. Role of transcriptional activation of IKBO in mediation of immunosuppression by glucocorticoids. Science 270, 283-286 (1995).
32. Auphan, N., DiDonato, J. A., Rosette, C, Helmberg, A. & Karin, M. Immunosuppression by glucocorticoids: inhibition of NF-KB activity through induction of IKB synthesis. Science 270, 286-290 (1995).
33. Rhen, T. & Cidlowski, J. A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N. Engl. J. Med. 353, 1711-1723 (2005).
34. Bornstein, S. R. Predisposing factors for adrenal insufficiency. N. Engl. J. Med. 360, 2328-2339 (2009).
35. Hebbar, K. B., Stockwell, J. A., Leong, T & Fortenberry, J. D. Incidence of adrenal insufficiency and impact of corticosteroid supplementation in critically ill children with systemic inflammatory syndrome and vasopressor-dependent shock. Crit. Care Med. 39, 1145-1150 (2011).
36. Maxime, V, Lesur, O. & Annane, D. Adrenal insufficiency in septic shock. Clin. Chest Med. 30, 17-27 (2009).
37. Annane, D. et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288, 862-871 (2002).
38. Sprung, C. L. et al. Hydrocortisone therapy for patients with septic shock. N. Engl. J. Med. 358, 111-124 (2008).
39. Davis, C. E. et al. Prevention of death from endotoxin with antisera. I. The risk of fatal anaphylaxis to endotoxin. J. Immunol. 102, 563-572 (1969).
40. Braude, A. I., Ziegler, E. J., Douglas, H. & McCutchan, J. A. Antibody to cell wall glycolipid of Gram-negative bacteria: induction of immunity to bacteremia and endotoxemia. J. Infect. Dis. 136, S167-S173 (1977).
41. Ziegler, E. J., Douglas, H. & Braude, A. I. Human antiserum for prevention of the local Shwartzman reaction and death from bacterial lipopolysaccharides. J. Clin. Invest. 52, 3236-3238 (1973).
42. Warren, H. S., Danner, R. L. & Munford, R. S. Anti-endotoxin monoclonal antibodies. N. Engl. J. Med. 326, 1153-1157 (1992).
43. Quezado, Z. M. et al. A controlled trial of HA-1A in a canine model of Gram-negative septic shock. JAMA 269, 2221-2227 (1993).
44. McCloskey, R. V et al. Treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 121, 1-5 (1994).
45. Mullarkey, M. et al. Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther 304, 1093-1102 (2003).
46. Ii, M. et al. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl] cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits Toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol. Pharmacol. 69, 1288-1295 (2006).
47. Meszaros, K. et al. A recombinant amino terminal fragment of bactericidal/permeability-increasing protein inhibits the induction of leukocyte responses by LPS. J. Leukoc. Biol. 54, 558-563 (1993).
48. Opal, S. M. et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 309, 1154-1162 (2013).
49. Tidswell, M. et al. Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis. Crit. Care Med. 38, 72-83 (2010).
50. Rice, T. W et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit. Care Med. 38, 1685-1694 (2010).
51. 21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 356, 961-967 (2000).
52. Spriggs, D. R. et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J. Natl Cancer Inst. 80, 1039-1044 (1988).
53. Lorente, J. A. & Marshall, J. C. Neutralization of tumor necrosis factor in preclinical models of sepsis. Shock 24 (Suppl. 1), 107-119 (2005).
54. Panacek, E. A. et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit. Care Med. 32, 2173-2182 (2004).
55. Qiu, P. et al. Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis. Crit. Care Med. 41, 2419-2429 (2013).
56. Crown, J. et al. A phase I trial of recombinant human interleukin-1 (3 alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood 78, 1420-1427 (1991).
57. Alexander, H. R., Doherty, G. M., Buresh, C. M., Venzon, D. J. & Norton, J. A. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J. Exp. Med. 173, 1029-1032 (1991).
58. Fisher, C. J. Jr et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit. Care Med. 22, 12-21 (1994).
59. Fisher, C. J. Jr et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271, 1836-1843 (1994).
60. Opal, S. M. et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit. Care Med. 25, 1115-1124 (1997).
61. Vincent, J. L, Spapen, H., Bakker, J., Webster, N. R. & Curtis, L. Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Crit. Care Med. 28, 638-642 (2000).
62. Schuster, D. P. et al. Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit. Care Med. 31, 1612-1619 (2003).
63. Opal, S. et al. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit. Care Med. 32, 332-341 (2004).
64. Dempfle, C. E. Disseminated intravascular coagulation and coagulation disorders. Curr. Opin. Anaesthesiol. 17, 125-129 (2004).
65. Creasey, A. A. et al. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J. Clin. Invest. 91, 2850-2860 (1993).
66. Taylor, F B. Jr et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J. Clin. Invest. 79, 918-925 (1987).
67. Emerson, T. E. Jr., Fournel, M. A., Redens, T. B. & Taylor, F B. Jr. Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia. Am. J. Med. 87, S27-S33 (1989).
68. Bernard, G. R. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699-709 (2001).
69. Abraham, E. et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N. Engl. J. Med. 353, 1332-1341 (2005).
70. Nadel, S. et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 369, 836-843 (2007).
71. Ranieri, V. M. et al. Drotrecogin alfa (activated) in adults with septic shock. N. Engl. J. Med. 366, 2055-2064 (2012).
72. Rodríguez, A. et al. Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock 23, 298-304 (2005).
73. Tugrul S. et al. The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]. Crit. Care 6, 357-362 (2002).
74. Guntupalli, K. et al. A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Crit. Care Med. 41, 706-716 (2013).
75. Ziegler, E. J. et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N. Engl. J. Med. 324, 429-436 (1991).
76. Fisher, C. J. Jr et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N. Engl. J. Med. 334, 1697-1702 (1996).
77. Lopez, A. et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit. Care Med. 32, 21-30 (2004).
78. Marra, M. N., Thornton, M. B., Snable, J. L., Wilde, C. G. & Scott, R. W. Endotoxin-binding and-neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5. Crit. Care Med. 22, 559-565 (1994).
79. Chen, T. Y. et al. Protective effects of anti-O polysaccharide and anti-lipid A monoclonal antibodies on pulmonary hemodynamics. J. Appl. Physiol. 74, 423-427 (1993).
80. van Deuren, M. et al. Plasma patterns of tumor necrosis factor-α (TNF) and TNF soluble receptors during acute meningococcal infections and the effect of plasma exchange. Clin. Infect. Dis. 26, 918-923 (1998).
81. Kellum, J. A. et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch. Intern. Med. 167, 1655-1663 (2007).
82. Deitch, E. A. Animal models of sepsis and shock: a review and lessons learned. Shock 9, 1-11 (1998).
83. van der Poll, T. Preclinical sepsis models. Surg. Infect. 13, 287-292 (2012).
84. Zanotti-Cavazzoni, S. L. & Goldfarb, R. D. Animal models of sepsis. Crit. Care Clin. 25, 703-719 (2009).
85. Fink, M. P. Animal models of sepsis and its complications. Kidney Int. 74, 991-993 (2008).
86. Ozment, T. R. et al. Scavenger receptor class A plays a central role in mediating mortality and the development of the pro-inflammatory phenotype in polymicrobial sepsis. PLoS Pathog. 8, e1002967 (2012).
87. Ulloa, L. et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc. Natl Acad. Sci. USA 99, 12351-12356 (2002).
88. Hollenberg, S. M. et al. Characterization of a hyperdynamic murine model of resuscitated sepsis using echocardiography. Am. J. Respir. Crit. Care Med. 164, 891-895 (2001).
89. Doerschug, K. C., Powers, L. S., Monick, M. M., Thorne, P. S. & Hunninghake, G. W. Antibiotics delay but do not prevent bacteremia and lung injury in murine sepsis. Crit. Care Med. 32, 489-494 (2004).
90. Teale, D. M. & Atkinson, A. M. Inhibition of nitric oxide synthesis improves survival in a murine peritonitis model of sepsis that is not cured by antibiotics alone. J. Antimicrob. Chemother. 30, 839-842 (1992).
91. Evans, T., Carpenter, A., Silva, A. & Cohen, J. Inhibition of nitric oxide synthase in experimental Gram-negative sepsis. J. Infect. Dis. 169, 343-349 (1994).
92. Sakiniene, E., Bremell, T. & Tarkowski, A. Inhibition of nitric oxide synthase (NOS) aggravates Staphylococcus aureus septicaemia and septic arthritis. Clin. Exp. Immunol. 110, 370-377 (1997).
93. Pettipher, E. R. & Wimberly, D. J. Cyclooxygenase inhibitors enhance tumour necrosis factor production and mortality in murine endotoxic shock. Cytokine 6, 500-503 (1994).
94. Wise, W. C., Cook, J. A., Eller, T. & Halushka, P. V. Ibuprofen improves survival from endotoxic shock in the rat. J. Pharmacol. Exp. Ther. 215, 160-164 (1980).
95. Whalley, E. T., Solomon, J. A., Modafferi, D. M., Bonham, K. A. & Cheronis, J. C. CP-0127, a novel potent bradykinin antagonist, increases survival in rat and rabbit models of endotoxin shock. Agents Actions Suppl. 38, 413-420 (1992).
96. De Kimpe, S. J., Thiemermann, C. & Vane, J. R. Role for intracellular platelet-activating factor in the circulatory failure in a model of Gram-positive shock. Br. J. Pharmacol. 116, 3191-3198 (1995).
97. Fink, M. P. Animal models of sepsis. Virulence 5, 143-153 (2013).
98. Pfeffer, K. et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73, 457-467 (1993).
99. Warren, H. S. et al. Resilience to bacterial infection: difference between species could be due to proteins in serum. J. Infect. Dis. 201, 223-232 (2010).
100. Glode, L. M., Mergenhagen, S. E. & Rosenstreich, D. L. Significant contribution of spleen cells in mediating the lethal effects of endotoxin in vivo. Infection Immun. 14, 626-630 (1976).
101. McCuskey, R. S., McCuskey, P. A., Urbaschek, R. & Urbaschek, B. Species differences in Kupffer cells and endotoxin sensitivity. Infection Immun. 45, 278-280 (1984).
102. Reynolds, K. et al. Pretreatment with troglitazone decreases lethality during endotoxemia in mice. J. Endotox. Res. 8, 307-314 (2002).
103. Barber, A. E. et al. Influence of hypercortisolemia on soluble tumor necrosis factor receptor II and interleukin-1 receptor antagonist responses to endotoxin in human beings. Surgery 118, 406-411 (1995).
104. Suffredini, A. F. et al. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J. Immunol. 155, 5038-5045 (1995).
105. Taveira da Silva, A. M. et al. Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N. Engl. J. Med. 328, 1457-1460 (1993).
106. Seok, J. et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl Acad. Sci. USA 110, 3507-3512 (2013).
107. Huh, D. et al. Reconstituting organ-level lung functions on a chip. Science 328, 1662-1668 (2010).
108. Miyaji, T. et al. Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney Int. 64, 1620-1631 (2003).
109. Zhou, M., Wu, R., Dong, W., Leong, J. & Wang, P. Accelerated apoptosis contributes to aging-related hyperinflammation in endotoxemia. Int. J. Mol. Med. 25, 929-935 (2010).
110. Nacionales, D. C. et al. Aged mice are unable to mount an effective myeloid response to sepsis. J. Immunol. 192, 612-622 (2014).
111. Chedid, L. & Parant, M. Study of the tolerance of adrenalectomized mice using an endotoxin labeled with Cr-51. Ann. l'Institut Pasteur 101, 170-177 (in French) (1961).
112. Galanos, C., Freudenberg, M. A. & Reutter, W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. Natl Acad. Sci. USA 76, 5939-5943 (1979).
113. Sveen, K., Hofstad, T. & Milner, K. C. Lethality for mice and chick embryos, pyrogenicity in rabbits and ability to gelate lysate from amoebocytes of Limulus polyphemus by lipopolysaccharides from Bacteroides, Fusobacterium and Veillonella. Acta Pathol. Microbiol. Scand. B 85B, 388-396 (1977)
114. Connor, D. G. & Kass, E. H. Effect of artificial fever in increasing susceptibility to bacterial endotoxin. Nature 190, 453-454 (1961).
115. David, J. M., Chatziioannou, A. F., Taschereau, R., Wang, H. & Stout, D. B. The hidden cost of housing practices: using noninvasive imaging to quantify the metabolic demands of chronic cold stress of laboratory mice. Comparative Med. 63, 386-391 (2013).
116. Karp, C. L. Unstressing intemperate models: how cold stress undermines mouse modeling. J. Exp. Med. 209, 1069-1074 (2012).
117. Unsinger, J., McDonough, J. S., Shultz, L. D., Ferguson, T. A. & Hotchkiss, R. S. Sepsis-induced human lymphocyte apoptosis and cytokine production in "humanized" mice. J. Leukoc. Biol. 86, 219-227 (2009).
118. Brehm, M. A., Shultz, L. D., Luban, J. & Greiner, D. L. Overcoming current limitations in humanized mouse research. J. Infecti. Diseases 208 (Suppl. 2), S125-S130 (2013).
119. Meurens, F., Summerfield, A., Nauwynck, H., Saif, L. & Gerdts, V. The pig: a model for human infectious diseases. Trends Microbiol. 20, 50-57 (2012).
120. Greenman, R. L. et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 266, 1097-1102 (1991).
121. Bone, R. C. et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit. Care Med. 23, 994-1006 (1995).
122. Angus, D. C. et al. E5 murine monoclonal antiendotoxin antibody in Gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA 283, 1723-1730 (2000).
123. Eichacker, P. Q. et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am. J. Respir. Crit. Care Med. 166, 1197-1205 (2002).
124. Minneci, P. C., Deans, K. J., Eichacker, P. Q. & Natanson, C. The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis. Clin. Microbiol. Infect. 15, 308-318 (2009).
125. Ramachandran, G. et al. A peptide antagonist of CD28 signaling attenuates toxic shock and necrotizing soft-tissue infection induced by Streptococcus pyogenes. J. Infect. Dis. 207, 1869-1877 (2013).
126. Bulger, E. M. et al. A novel drug for treatment of necrotizing soft-tissue infections: a randomized clinical trial. JAMA Surg. 149, 528-536 (2014).
127. Giroir, B. P. et al. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet 350, 1439-1443 (1997).
128. Tracey, K. J. & Warren, H. S. Human genetics: an inflammatory issue. Nature 429, 35-37 (2004).
129. Gaddnas, F. P. et al. Matrix-metalloproteinase-2,-8 and-9 in serum and skin blister fluid in patients with severe sepsis. Crit. Care 14, R49 (2010).
130. Lauhio, A. et al. Serum MMP-8,-9 and TIMP-1 in sepsis: high serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines. Pharmacol. Res. 64, 590-594 (2011).
131. Solan, P. D. et al. A novel role for matrix metalloproteinase-8 in sepsis. Crit. Care Med. 40, 379-387 (2012).
132. Fink, M. P. Matrix metalloproteinase-8 as a potential drug target for the therapy of sepsis. Crit. Care Med. 40, 655-656 (2012).
133. US Food and Drug Administration. Draft Guidance for Industry: adaptive design clinical trials for drugs and biologics. FDA [online], http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf (2010).
134. Kairalla, J. A., Coffey, C. S., Thomann, M. A. & Muller, K. E. Adaptive trial designs: a review of barriers and opportunities. Trials 13, 145 (2012).
135. Kumar, A. et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med. 34, 1589-1596 (2006).
136. Warren, H. S. et al. A genomic score prognostic of outcome in trauma patients. Mol. Med. 15, 220-227 (2009).
137. Semmler, A. et al. Persistent cognitive impairment, hippocampal atrophy and EEG changes in sepsis survivors. J. Neurol. Neurosurg. Psychiatry 84, 62-69 (2013).
138. Herridge, M. S. et al. Functional disability 5 years after acute respiratory distress syndrome. N. Engl. J. Med. 364, 1293-1304 (2011).
139. a receptor full agonist for the treatment of vasodilatory hypotension. J. Pharmacol. Exp. Ther. 337, 786-796 (2011).
140. Doi, K. et al. AP214, an analogue of α-melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney injury and mortality. Kidney Int. 73, 1266-1274 (2008).
141. Pickkers, P. et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit. Care 16, R14 (2012).
142. Zou, L. et al. Complement factor B is the downstream effector of TLRs and plays an important role in a mouse model of severe sepsis. J. Immunol. 191, 5625-5635 (2013).
143. Petronilho, F., Danielski, L. G., Roesler, R., Schwartsmann, G. & Dal-Pizzol, F Gastrin-releasing peptide as a molecular target for inflammatory diseases: an update. Inflamm. Allergy Drug Targets 12, 172-177 (2013).
144. Koh, G. C. et al. Glyburide reduces bacterial dissemination in a mouse model of melioidosis. PLoS Negl. Trop. Dis. 7, e2500 (2013).
145. Yang, M. et al. Chloroquine inhibits HMGB1 inflammatory signaling and protects mice from lethal sepsis. Biochem. Pharmacol. 86, 410-418 (2013).
146. Hurle, M. R. et al. Computational drug repositioning: from data to therapeutics. Clin. Pharmacol. Ther. 93, 335-341 (2013).
147. Sprung, C. L. et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N. Engl. J. Med. 311, 1137-1143 (1984).
148. Bone, R. C. et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 317, 653-658 (1987).
149. Abraham, E. et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-α MAb Sepsis Study Group. JAMA 273, 934-941 (1995).
150. Cohen, J. & Carlet, J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit. Care Med. 24, 1431-1440 (1996).
151. Abraham, E. et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 351, 929-933 (1998).
152. Dhainaut, J. F et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit. Care Med. 22, 1720-1728 (1994).
153. Dhainaut, J. F et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit. Care Med. 26, 1963-1971 (1998).
154. Abraham, E. et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290, 238-247 (2003).
155. Wunderink, R. G. et al. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am. J. Respir. Crit. Care Med. 183, 1561-1568 (2011).
156. Vincent, J. L. et al. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit. Care Med. 41, 2069-2079 (2013).
157. Root, R. K. et al. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit. Care Med. 31, 367-373 (2003).
158. Meisel, C. et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am. J. Respir. Crit. Care Med. 180, 640-648 (2009).
159. Fein, A. M. et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA 277, 482-487 (1997).
160. Dellinger, R. P. et al. Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Crit. Care Med. 37, 2929-2938 (2009).
161. Bernard, G. R. et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen Sepsis Study Group. N. Engl. J. Med. 336, 912-918 (1997).
162. Fischer, E. et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J. Clin. Invest. 89, 1551-1557 (1992).
163. Hinshaw, L. B. et al. Effectiveness of steroid/antibiotic treatment in primates administered LD100 Escherichia coli. Ann. Surg. 194, 51-56 (1981).
164. Villa, P. et al. Granulocyte colony-stimulating factor and antibiotics in the prophylaxis of a murine model of polymicrobial peritonitis and sepsis. J. Infect. Dis. 178, 471-477 (1998).
165. Babalola, C. P., Nightingale, C. H. & Nicolau, D. P. Adjunctive efficacy of granulocyte colony-stimulating factor on treatment of Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts. J. Antimicrob. Chemother. 53, 1098-1100 (2004).
166. Van Zee, K. J. et al. Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. J. Immunol. 156, 2221-2230 (1996).
167. Redl, H. et al. Endogenous modulators of TNF and IL-1 response are under partial control of TNF in baboon bacteremia. Am. J. Physiol. 271, R1193-R1198 (1996).
168. Myers, A. K., Robey, J. W. & Price, R. M. Relationships between tumour necrosis factor, eicosanoids and platelet-activating factor as mediators of endotoxin-induced shock in mice. Br. J. Pharmacol. 99, 499-502 (1990).
169. Giral, M. et al. Effects of UR-12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic shock. Br. J. Pharmacol. 118, 1223-1231 (1996).
170. Ogata, M. et al. An antagonist of platelet-activating factor suppresses endotoxin-induced tumor necrosis factor and mortality in mice pretreated with carrageenan. Infection Immun. 61, 699-704 (1993).
171. Takashima, K. et al. Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br. J. Pharmacol. 157, 1250-1262 (2009).
172. Sha, T. et al. Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur. J. Pharmacol. 571, 231-239 (2007).
173. Camerota, A. J., Creasey, A. A., Patla, V., Larkin, V. A. & Fink, M. P. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with Gram-negative peritonitis. J. Infect. Dis. 177, 668-676 (1998).
174. Opal, S. M., Palardy, J. E., Parejo, N. A. & Creasey, A. A. The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis. Crit. Care Med. 29, 13-17 (2001).
175. Lin, C. W. et al. Complete activation of autophagic process attenuates liver injury and improves survival in septic mice. Shock 41, 241-249 (2013).
176. Papareddy, P. et al. The TFPI-2 derived peptide EDC34 improves outcome of Gram-negative sepsis. PLoS Pathog. 9, e1003803 (2013).
177. Qiang, X. et al. Cold-inducible RNA-binding protein (CIRP) triggers inflammatory responses in hemorrhagic shock and sepsis. Nature Med. 19, 1489-1495 (2013).
178. Holthoff, J. H., Wang, Z., Patil, N. K., Gokden, N. & Mayeux, P. R. Rolipram improves renal perfusion and function during sepsis in the mouse. J. Pharmacol. Exp. Ther. 347, 357-364 (2013).